Ken Griffin
CGTX icon

Ken Griffin’s Cognition Therapeutics CGTX Stock Holding History

Ken Griffin’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7K Sell
25,905
-135,296
-84% -$157K ﹤0.01% 12674
2025
Q4 		$218K Buy
+161,201
New +$262K ﹤0.01% 10861
2024
Q3 		– Sell
-26,950
Closed -$44.7K – 14314
2024
Q2 		$44.7K Buy
+26,950
New +$53.7K ﹤0.01% 11892
2022
Q2 		– Sell
-10,504
Closed -$28K – 12968
2022
Q1 		$28K Buy
+10,504
New +$40.5K ﹤0.01% 13127

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Ken Griffin's CGTX Position: Q1 2026 in Review

Ken Griffin reduced its Cognition Therapeutics (CGTX) stake by 84% in Q1 2026, selling an estimated $157K and leaving 25,905 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12674.

Ken Griffin first reported a position in CGTX in Q1 2022 and has held it in 4 quarters since. The position peaked at $218K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Ken Griffin held 25,905 shares of Cognition Therapeutics worth $19.7K as of Q1 2026.
  • Ken Griffin sold 135,296 Cognition Therapeutics shares in Q1 2026, an estimated $157K.
  • Cognition Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12674 holding.
  • Ken Griffin first reported a position in Cognition Therapeutics in Q1 2022 and has held it in 4 quarters since.
  • Ken Griffin's Cognition Therapeutics position peaked at $218K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.